Skip to main content
OpenTrials
Completed

NCT Number: NCT01380587

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Lymphoblastic Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Leukemia, Lymphoid Lymphatic Diseases Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Precursor Cell Lymphoblastic Leukemia-Lymphoma

Age range

1 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitario Dr. Jose E. Gonzalez UANL

Monterrey, Nuevo León, 64460, Mexico

About this study

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion criteria

  • Patients with prior treatment with chemotherapeutic agents.
  • Patients treated with immunosuppressants.
  • Patients under 12 months old.
  • Patients with a diagnosis or history of autoimmune diseases.
  • Patients with a diagnosis or history of immunosuppressive diseases.
  • Patients who do not agree to sign a Letter of Informed Consent.

Treatment and study plan

Primary outcomes

  1. Number of patients with poor prognosis and high levels of XCL1

    Time frame: 3 months

    Number of patients with high levels of XCL1, expression of its receptor and other cytokines.

  2. Number of patients with poor prognosis and high levels of cytokines

    Time frame: 3 months

    Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.

Sponsors and collaborators

Lead sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Other

Registry information

Acronym: XCL1

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jun 27, 2011
Registry last updated
Aug 27, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.